CHA₂DS₂-VASc Score Calculator

CHA₂DS₂-VASc Score Calculator for Cardiology. Higher scores predict progressively higher annual thromboembolic risk, from well under 1% at a score of 0 to double digits at scores of 7–9. Guidelines translate these bands into action: in men, a score of 0 (or 1 in women, where the point is from sex alone) generally supports withholding anticoagulation; a score of 1 in men or 2 in women is an intermediate zone where anticoagulation should be considered; and a score of ≥2 in men or ≥3 in women warrants oral anticoagulation, preferably a DOAC over warfarin in eligible patients. Female sex is treated as a risk modifier rather than an independent trigger, so it does not by itself move a patient into the treatment category.

How this calculator works

The score sums points across seven clinical factors to estimate annual thromboembolic risk in non-valvular atrial fibrillation. One point each is assigned for congestive heart failure/LV dysfunction, hypertension, diabetes, vascular disease (prior MI, peripheral artery disease, or aortic plaque), age 65–74, and female sex; two points each for age ≥75 and prior stroke/TIA/thromboembolism. The total ranges from 0 to 9 and maps to a published annual stroke rate, with the doubled weighting of prior stroke and advanced age reflecting their outsized predictive value.

When to use this calculator

Use it in patients with confirmed non-valvular atrial fibrillation or atrial flutter to decide whether oral anticoagulation is warranted. It refined the older CHADS₂ score specifically to better classify patients previously labelled "low risk." Do not apply it to patients with moderate-to-severe mitral stenosis or a mechanical heart valve (who require anticoagulation regardless), and it is not a bleeding-risk tool — pair it with a bleeding assessment such as HAS-BLED when weighing therapy.

Inputs used

  • Heart failure
  • Hypertension
  • Age
  • Diabetes
  • Stroke or TIA history
  • Vascular disease
  • Sex category

Clinical interpretation

Higher scores predict progressively higher annual thromboembolic risk, from well under 1% at a score of 0 to double digits at scores of 7–9. Guidelines translate these bands into action: in men, a score of 0 (or 1 in women, where the point is from sex alone) generally supports withholding anticoagulation; a score of 1 in men or 2 in women is an intermediate zone where anticoagulation should be considered; and a score of ≥2 in men or ≥3 in women warrants oral anticoagulation, preferably a DOAC over warfarin in eligible patients. Female sex is treated as a risk modifier rather than an independent trigger, so it does not by itself move a patient into the treatment category.

Worked example

A 78-year-old woman with hypertension and type 2 diabetes but no prior stroke scores: age ≥75 (2) + female sex (1) + hypertension (1) + diabetes (1) = 5. A score of 5 corresponds to an adjusted annual stroke risk of roughly 7%, placing her firmly in the high-risk category where oral anticoagulation is recommended over antiplatelet therapy or no treatment.

Limitations and safety notes

Female sex contributes risk mainly when at least one other non-sex factor is present, so a woman whose only point is sex has a stroke risk comparable to a low-risk man, and treating the score literally can overestimate her need for anticoagulation. The score has only modest discrimination (c-statistic around 0.6) and does not incorporate AF burden, renal function, obesity, or biomarkers, so it is a crude risk stratifier rather than a precise predictor. It is validated for non-valvular AF and should not be extended to valvular AF, and reported event rates vary substantially across the cohorts in which it has been examined.

Frequently asked questions

How is CHA₂DS₂-VASc different from the older CHADS₂ score?

CHA₂DS₂-VASc adds three factors CHADS₂ omitted — vascular disease, age 65–74, and female sex — and doubles the weight of age ≥75. Its main advantage is better identifying truly low-risk patients who can safely avoid anticoagulation, rather than improving discrimination at the high end.

At what score should I start oral anticoagulation?

Anticoagulation is recommended at a score of ≥2 in men and ≥3 in women. A score of 1 in men or 2 in women is an intermediate category where it should be considered based on individual bleeding risk and preferences. DOACs are preferred over warfarin in patients without mechanical valves or moderate-to-severe mitral stenosis.

Does a woman with an isolated point for sex need anticoagulation?

No. Female sex is an age-dependent risk modifier, not a standalone indication. A woman whose only point comes from sex carries a stroke risk similar to a low-risk man and generally does not require anticoagulation.

Can I use this score in patients with a mechanical valve or mitral stenosis?

No. It is validated only for non-valvular AF. Patients with mechanical heart valves or moderate-to-severe mitral stenosis need anticoagulation regardless of score, and those specific groups require warfarin rather than a DOAC.

Does the score assess bleeding risk?

No. It estimates only thromboembolic (stroke) risk. Bleeding risk must be assessed separately, for example with HAS-BLED, so that the net clinical benefit of anticoagulation can be weighed.

References

  • Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272. PMID: 19762550.
  • Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870. PMID: 11401607.
  • Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. PMID: 38033089.
  • Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. PMID: 32860505.

Editorial review and citation methodology

Reviewed by the Quick Medical Calculator Editorial Team. Last reviewed: March 6, 2026. The review checks calculator inputs, intended population, interpretation, limitations, and source alignment.

  • Prefer original validation studies for scoring systems and prediction tools.
  • Use current specialty society guidance, transplant allocation policy, public health guidance, or regulator resources when they govern clinical use.
  • Include limitations and safety notes when a calculator is population-specific, context-dependent, or unsuitable as a standalone decision tool.

Related reviewed calculators